Journal article
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe
Antimicrobial agents and chemotherapy, Vol.64(5), e00211-20
04/21/2020
DOI: 10.1128/AAC.00211-20
PMID: 32094135
Abstract
Nine hundred
clinical isolates from 83 U.S. and European medical centers were tested for susceptibility by reference broth microdilution methods against ceftolozane-tazobactam and comparators. Results were stratified by β-lactamase production and infection type. Overall, ceftolozane-tazobactam MIC
values were 0.12/0.25 mg/liter, and 99.0% of isolates were inhibited at the susceptible breakpoint of ≤0.5 mg/liter; the highest MIC value was only 2 mg/liter. Our results support using ceftolozane-tazobactam to treat
infections.
Details
- Title: Subtitle
- Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe
- Creators
- Helio S Sader - JMI LaboratoriesCecilia G Carvalhaes - JMI LaboratoriesLeonard R Duncan - JMI LaboratoriesDee Shortridge - JMI Laboratories
- Resource Type
- Journal article
- Publication Details
- Antimicrobial agents and chemotherapy, Vol.64(5), e00211-20
- DOI
- 10.1128/AAC.00211-20
- PMID
- 32094135
- ISSN
- 0066-4804
- eISSN
- 1098-6596
- Grant note
- DOI: 10.13039/100009947, name: Merck & Co., Inc. | Merck Sharp and Dohme
- Language
- English
- Date published
- 04/21/2020
- Academic Unit
- Microbiology and Immunology; Pathology
- Record Identifier
- 9984185276002771
Metrics
21 Record Views